GSK decides against selling established portfolio brands; More solid data for Pfizer's Xalkori;

@FiercePharma: Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. FierceVaccines article | Follow @FiercePharma

@EricPFierce: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. News | Follow @EricPFierce

@CarlyHFierce: Universal flu vaccine developer BiondVax mulling IPO. Globes | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) today said it had decided against selling off its portfolio of older drugs. Release

> An estimated 58,000 newborns in India died last year from antibiotic resistant infections, a number being described as an epidemic. Story

> Pfizer ($PFE) says data from a Phase III study shows that its targeted cancer drug Xalkori (crizotinib) significantly extended progression-free survival in previously-untreated patients with a particular form of non-small cell lung cancer. Story

> Pfizer will share information on drugs with the World Anti-Doping Agency (WADA) to allow it to test for performance-enhancing substances in athletes. Story

> The FDA approved Amgen's ($AMGN) Blincyto (blinatumomab), the first of a new class of immunotherapies that promise to change the standard of care in blood cancer. Story

> The FDA has established new standards for using prescription drugs by women who are breastfeeding children. Release

Medical Device News

@FierceMedDev: ICYMI: Illumina and Sequenom lay ongoing prenatal diagnostic patent feud to rest. Article | Follow @FierceMedDev

@EmilyWFierce: Britain's BTG scoops up pulmonology outfit PneumRx for up to $475M. Story | Follow @EmilyWFierce

> Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition. Item

> Hospital requires use of wireless, wearable sensors to prevent bedsores. News

> HeartFlow's noninvasive test for coronary artery disease cleared by FDA. More

Biotech News

@FierceBiotech: Party time at Array as Novartis bows out of PhIII binimetinib cancer program. Report | Follow @FierceBiotech

@JohnCFierce: College students with big ideas can shoot for some seed money from Xfund. Harvard-based--$100M. More from the WSJ | Follow @JohnCFierce

@DamianFierce: Blincyto, which sounds like it's related to the cells of blintzes, is the name of Amgen's new cancer drug. More | Follow @DamianFierce

> Scientists herald a breakthrough in reversing spinal damage. More

> J&J launches PhII lymphoma study for daratumumab. Item

> Biotech partners at Allena fund a march toward PhIII with $25M venture round. Report

Vaccines News

> Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. Article

> Universal flu vax developer BiondVax mulling IPO: Globes. Item

> GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI. Report

> Merck, NewLink Ebola vaccine trial shows no serious side effects so far. Story

> Novartis' Fluad off the hook in Italy following 19 deaths. Article

Pharma Manufacturing News

> EMA clears Novartis Fluad in deaths in Italy. Item

> Johnson Matthey buys former Glaxo facility in Scotland. More

> Strides Arcolab begins construction of $60M Malaysia facility. Report

> Some Indian drugmakers routinely toss out bad test results: Bloomberg. Story

> Germany, EU, join U.S. in banning India-made Ranbaxy products. Article

And finally... Healthcare spending was up 3.6% in the U.S. last year, the smallest rise in more than half a century. Story

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.